[{"id":"e32f44a1-6c83-4eeb-afea-f28ff7b0d2a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914794","created_at":"2025-08-02T14:12:26.243Z","updated_at":"2025-08-02T14:12:26.243Z","phase":"Phase 2","brief_title":"A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors","source_id_and_acronym":"NCT03914794","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FGFR3","pipe":"","alterations":" ","tags":["FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 10/02/2020","start_date":" 10/02/2020","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-05-21"},{"id":"0f9bc919-4e69-4675-bc62-35e94a94fa58","acronym":"INT22-09-01","url":"https://clinicaltrials.gov/study/NCT05521698","created_at":"2022-08-30T20:56:03.144Z","updated_at":"2025-02-25T13:41:12.118Z","phase":"Phase 1","brief_title":"Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT05521698 - INT22-09-01","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/23/2025","start_date":" 04/23/2025","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2025-02-21"},{"id":"5c88c63c-d256-4f58-81e6-5b70704df6d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06632262","created_at":"2025-02-26T15:04:35.295Z","updated_at":"2025-02-26T15:04:35.295Z","phase":"Phase 2","brief_title":"A Phase 2 Clinical Study of ABSK061 and ABSK043","source_id_and_acronym":"NCT06632262","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" HER-2 • FGFR2 • FGFR3","pipe":"","alterations":" ","tags":["HER-2 • FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK043 • lavengratinib (ABSK061)"],"overall_status":"Recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 11/13/2024","start_date":" 11/13/2024","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2024-11-19"},{"id":"1d4ba0e5-2e91-4eb0-9b78-dcfdf4bea1c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564416","created_at":"2022-10-03T15:56:45.916Z","updated_at":"2024-07-02T16:35:16.428Z","phase":"Phase 2","brief_title":"Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial","source_id_and_acronym":"NCT05564416","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR3","pipe":" | ","alterations":" FGFR fusion","tags":["PD-L1 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • Balversa (erdafitinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/12/2023","start_date":" 10/12/2023","primary_txt":" Primary completion: 11/03/2023","primary_completion_date":" 11/03/2023","study_txt":" Completion: 11/03/2023","study_completion_date":" 11/03/2023","last_update_posted":"2024-03-05"},{"id":"b9fc72c6-a859-48f1-9e18-9b0ad1b87be8","acronym":"URODX-FGFR3","url":"https://clinicaltrials.gov/study/NCT05151341","created_at":"2021-12-09T18:00:20.204Z","updated_at":"2024-07-02T16:35:41.577Z","phase":"","brief_title":"Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors","source_id_and_acronym":"NCT05151341 - URODX-FGFR3","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" FGFR3","pipe":"","alterations":" ","tags":["FGFR3"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-07-28"},{"id":"ab7410d8-2300-42e7-99c4-950787c11580","acronym":"","url":"https://clinicaltrials.gov/study/NCT02872714","created_at":"2021-01-17T17:44:53.147Z","updated_at":"2024-07-02T16:35:52.533Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)","source_id_and_acronym":"NCT02872714","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR3 • FGFR","pipe":" | ","alterations":" FGFR3 mutation • FGFR3 fusion","tags":["FGFR3 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 263","initiation":"Initiation: 01/12/2017","start_date":" 01/12/2017","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 02/01/2022","study_completion_date":" 02/01/2022","last_update_posted":"2023-03-24"},{"id":"405d6ea7-5fc5-409a-a4df-9eea87372fc1","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT04945148","created_at":"2021-06-30T17:54:14.680Z","updated_at":"2024-07-02T16:35:54.530Z","phase":"Phase 2","brief_title":"Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide","source_id_and_acronym":"NCT04945148 - OPTIMUM","lead_sponsor":"Hopital Foch","biomarkers":" FGFR3 • TACC3","pipe":" | ","alterations":" FGFR3 fusion • IDH wild-type","tags":["FGFR3 • TACC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 fusion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 640","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-02-28"},{"id":"a20d813c-0be4-46f6-9eac-b9a7b8cfecb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05187767","created_at":"2022-01-12T15:53:45.698Z","updated_at":"2024-07-02T16:36:00.723Z","phase":"","brief_title":"Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs","source_id_and_acronym":"NCT05187767","lead_sponsor":"University of Roma La Sapienza","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-11-08"},{"id":"290b7fc0-2551-4b8e-8a40-119d81d3738c","acronym":"VitDURO","url":"https://clinicaltrials.gov/study/NCT04197089","created_at":"2021-01-18T20:27:15.791Z","updated_at":"2024-07-02T16:36:06.166Z","phase":"Phase 4","brief_title":"Biological Effect of Vitamin D in Patients With Urothelial Carcinoma","source_id_and_acronym":"NCT04197089 - VitDURO","lead_sponsor":"Germans Trias i Pujol Hospital","biomarkers":" FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5","pipe":"","alterations":" ","tags":["FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 11/22/2021","primary_completion_date":" 11/22/2021","study_txt":" Completion: 11/22/2021","study_completion_date":" 11/22/2021","last_update_posted":"2022-08-03"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"bbd1a478-a3ea-4485-aa56-e8b3f93758ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT01975701","created_at":"2021-01-18T08:59:44.203Z","updated_at":"2024-07-02T16:36:52.939Z","phase":"Phase 2","brief_title":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","source_id_and_acronym":"NCT01975701","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1","pipe":" | ","alterations":" FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation","tags":["FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 12/09/2013","start_date":" 12/09/2013","primary_txt":" Primary completion: 10/03/2018","primary_completion_date":" 10/03/2018","study_txt":" Completion: 10/03/2018","study_completion_date":" 10/03/2018","last_update_posted":"2019-12-04"},{"id":"4e06d46a-253b-484d-a0a2-bca662c63ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT01004224","created_at":"2021-01-17T17:13:53.960Z","updated_at":"2024-07-02T16:36:54.872Z","phase":"Phase 1","brief_title":"A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT01004224","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3","pipe":" | ","alterations":" FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification","tags":["FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 12/11/2009","start_date":" 12/11/2009","primary_txt":" Primary completion: 10/08/2018","primary_completion_date":" 10/08/2018","study_txt":" Completion: 10/08/2018","study_completion_date":" 10/08/2018","last_update_posted":"2019-10-04"},{"id":"f641c387-9075-4449-bb2e-fb7b8991c607","acronym":"","url":"https://clinicaltrials.gov/study/NCT02745301","created_at":"2021-01-18T13:26:59.380Z","updated_at":"2024-07-02T16:37:07.944Z","phase":"","brief_title":"Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder","source_id_and_acronym":"NCT02745301","lead_sponsor":"Vanderbilt University","biomarkers":" TP53 • PIK3CA • FGFR3 • CDKN2A • TERT • TWIST1 • ONECUT2","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • PIK3CA • FGFR3 • CDKN2A • TERT • TWIST1 • ONECUT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2018-08-13"}]